###begin article-title 0
###xml 130 138 <span type="species:ncbi:9606">Patients</span>
Strong Association of a Common Dihydropyrimidine Dehydrogenase Gene Polymorphism with Fluoropyrimidine-Related Toxicity in Cancer Patients
###end article-title 0
###begin p 1
Conceived and designed the experiments: EG BB MR HGK MK FL AM. Performed the experiments: BB SN. Analyzed the data: EG BB MR SN KS. Contributed reagents/materials/analysis tools: EG BB MR KS HGK MK FL AM. Wrote the paper: EG MR FL AM. Final reading of manuscript: KS HGK MK.
###end p 1
###begin p 2
Current address: Department of Psychiatry and Psychotherapy, Universitat des Saarlandes, Homburg/Saar, Germany
###end p 2
###begin title 3
Background
###end title 3
###begin p 4
###xml 80 84 80 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DPYD</italic>
###xml 505 509 505 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DPYD</italic>
###xml 7 15 <span type="species:ncbi:9606">patients</span>
Cancer patients carrying mutations in the dihydropyrimidine dehydrogenase gene (DPYD) have a high risk to experience severe drug-adverse effects following chemotherapy with fluoropyrimidine drugs such as 5-fluorouracil (5-FU) or capecitabine. The pretreatment detection of this impairment of pyrimidine catabolism could prevent serious, potentially lethal side effects. As known deleterious mutations explain only a limited proportion of the drug-adverse events, we systematically searched for additional DPYD variations associated with enhanced drug toxicity.
###end p 4
###begin title 5
Methodology/Principal Findings
###end title 5
###begin p 6
###xml 82 86 82 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DPYD</italic>
###xml 665 674 665 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p (trend)</italic>
###xml 682 695 682 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p (corrected)</italic>
###xml 123 131 <span type="species:ncbi:9606">patients</span>
###xml 850 858 <span type="species:ncbi:9606">patients</span>
###xml 934 942 <span type="species:ncbi:9606">patients</span>
We performed a whole gene approach covering the entire coding region and compared DPYD genotype frequencies between cancer patients with good (n = 89) and with poor (n = 39) tolerance of a fluoropyrimidine-based chemotherapy regimen. Applying logistic regression analysis and sliding window approaches we identified the strongest association with fluoropyrimidine-related grade III and IV toxicity for the non-synonymous polymorphism c.496A>G (p.Met166Val). We then confirmed our initial results using an independent sample of 53 individuals suffering from drug-adverse-effects. The combined odds ratio calculated for 92 toxicity cases was 4.42 [95% CI 2.12-9.23]; p (trend)<0.001; p (corrected) = 0.001; the attributable risk was 56.9%. Comparing tumor-type matched sets of samples, correlation of c.496A>G with toxicity was particularly present in patients with gastroesophageal and breast cancer, but did not reach significance in patients with colorectal malignancies.
###end p 6
###begin title 7
Conclusion
###end title 7
###begin p 8
###xml 86 90 86 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DPYD</italic>
Our results show compelling evidence that, at least in distinct tumor types, a common DPYD polymorphism strongly contributes to the occurrence of fluoropyrimidine-related drug adverse effects. Carriers of this variant could benefit from individual dose adjustment of the fluoropyrimidine drug or alternate therapies.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 175 178 175 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Rivera1">[1]</xref>
###xml 179 182 179 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Sun1">[5]</xref>
###xml 510 513 510 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Heggie1">[6]</xref>
###xml 514 517 514 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-vanKuilenburg1">[8]</xref>
###xml 699 702 699 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Saif1">[9]</xref>
###xml 645 653 <span type="species:ncbi:9606">patients</span>
###xml 738 746 <span type="species:ncbi:9606">patients</span>
5-fluorouracil (5-FU) and orally available 5-FU prodrugs remain a backbone of chemotherapy for locally advanced and metastatic gastroesophageal, colorectal, and breast cancer [1]-[5], but can result in toxic effects. Severe and unpredictable drug-adverse events are mainly attributed to deficiency of the enzyme dihydropyrimidine dehydrogenase (DPD). Due to its function as initial and rate-limiting enzyme in the catabolism of pyrimidines, DPD deactivates more than 80% of administered standard doses of 5-FU [6]-[8]. The impairment of this pyrimidine degradation pathway leads to toxic accumulation of the drug and, most likely, concerns also patients treated with 5-FU-prodrugs like capecitabine [9]. Estimating a frequency of 3-5% of patients harbouring at least a partial DPD deficiency, the pretherapeutical detection of this metabolic dysfunction could prevent severe and unwanted side effects due to fluoropyrimidine drugs.
###end p 10
###begin p 11
###xml 97 101 97 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DPYD</italic>
###xml 116 120 116 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Yokota1">[10]</xref>
###xml 246 250 246 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Diasio2">[11]</xref>
###xml 251 255 251 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Ridge1">[16]</xref>
###xml 266 270 266 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DPYD</italic>
###xml 488 492 488 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-vanKuilenburg2">[17]</xref>
###xml 630 634 630 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-CollieDuguid1">[18]</xref>
###xml 635 639 635 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Schwab1">[20]</xref>
###xml 818 822 818 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-vanKuilenburg3">[21]</xref>
###xml 823 827 823 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Dobritzsch1">[23]</xref>
###xml 53 58 <span type="species:ncbi:9606">human</span>
###xml 479 487 <span type="species:ncbi:9606">patients</span>
After the characterization of the highly polymorphic human dihydropyrimidine dehydrogenase gene (DPYD, MIM# 274270) [10], rapid genetic testing has become feasible and numerous sequence aberrations have been found in different ethnic populations [11]-[16]. Specific DPYD variants result in a truncated protein with clear deleterious effect to the enzyme including the exon-14-skipping mutation IVS14+1g>a which has been considered as the most prevalent mutation in DPD deficient patients [17]. However, such truncating mutations have appeared to explain only a limited number of serious side effects attributed to DPD deficiency. [18]-[20]. Moreover, only few missense mutations are known to directly interfere with protein structure, cofactor binding or electron transfer of the DPD enzyme (e.g. c.703C>T; c.2846A>T) [21]-[23]. Up to now, the impact of (common) non-synonymous polymorphisms on fluoropyrimidine-induced toxicity remains widely unclear and systematic association studies are therefore mandatory.
###end p 11
###begin p 12
###xml 139 143 139 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-vanKuilenburg4">[24]</xref>
###xml 145 149 145 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Gross1">[25]</xref>
###xml 229 233 229 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Johnson1">[26]</xref>
###xml 325 333 <span type="species:ncbi:9606">patients</span>
###xml 377 385 <span type="species:ncbi:9606">patients</span>
In this context, the sequence variation c.496A>G (p.Met166Val) has been classified either as a mutation which is related to DPD deficiency [24], [25] or as a variant accompanied with normal DPD activity in peripheral blood cells [26]. Here we are presenting data showing a high prevalence of the c.496G risk allele in cancer patients with increased toxic reactions compared to patients with good tolerance of a fluoropyrimidine-containing chemotherapy.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
Objectives
###end title 14
###begin p 15
###xml 96 100 96 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DPYD</italic>
In this study, we thoroughly evaluated the risk of several genetic variants covering the entire DPYD gene for association with enhanced toxicity during standard fluoropyrimidine-based chemotherapy.
###end p 15
###begin title 16
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
Participants
###end title 16
###begin p 17
###xml 163 170 163 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004003-t001">Table 1</xref>
###xml 233 241 233 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004003.s001">Table S1</xref>
###xml 12 19 <span type="species:ncbi:9606">patient</span>
Our initial patient sample (n = 128) consisted of Caucasian subjects that had been diagnosed for breast, gastroesophageal and colorectal cancer between 2003-2006 (Table 1) and who received treatment with 5-FU-based therapy regimens (Table S1, supporting information) at the Klinikum rechts der Isar, Technische Universitat Munchen; the Klinikum Hamburg-Eppendorf and at other institutions in Germany.
###end p 17
###begin title 18
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient characteristics.
###end title 18
###begin p 19
Chemotherapy contained 5-FU, but other components not specified.
###end p 19
###begin p 20
###xml 116 120 <span type="species:ncbi:162683">Mayo</span>
Abbreviations: PLF, cisplatin, 5-fluorouracil, folinic acid; OLF/FOLFOX, oxaliplatin, 5-fluorouracil, folinic acid; Mayo protocol, 5-fluorouracil, folinic acid; FOLFIRI, irinotecan, 5-fluorouracil, folinic acid; CMF, cyclophosphamide, methotrexate, 5-fluorouracil; FEC, 5-fluorouracil, epirubicin, cyclophosphamide.
###end p 20
###begin p 21
###xml 125 129 125 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DPYD</italic>
###xml 297 304 297 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004003-t001">Table 1</xref>
###xml 320 328 320 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004003.s001">Table S1</xref>
###xml 484 488 484 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Scheithauer1">[27]</xref>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
###xml 170 175 <span type="species:ncbi:9606">Human</span>
For replication of our results, we included an additional cohort of 53 cancer patients who had been independently genotyped (DPYD exons 2, 6, 13 and 14) by the Center of Human Genetics and Laboratory Medicine, Munich-Martinsried, Germany, during 2005-2007 because of acute drug-adverse reactions (Table 1, cohort 2; and Table S1). Among these subjects, 14 had received therapies containing the orally available 5-FU prodrug capecitabine (Xeloda, Hoffmann LaRoche Pharma, Switzerland, [27]).
###end p 21
###begin p 22
###xml 100 104 100 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Seck1">[28]</xref>
In addition, a previously analyzed cohort of 157 healthy individuals without a background of cancer [28] was considerably enlarged up to 607 volunteers and genotyped for the variants c.496A>G (rs2297595) and IVS10-15t>c.
###end p 22
###begin title 23
Ethics
###end title 23
###begin p 24
Written informed consent had been obtained from all participating subjects and the study had been approved by the local Ethics Committee.
###end p 24
###begin title 25
Toxicity assessment
###end title 25
###begin p 26
Side-effects that are typically associated with 5-FU treatment, like neutropenia, thrombopenia, mucositis, diarrhea, nausea and vomiting, neurotoxicity, cardiac toxicity, alopecia and hand-foot-syndrome were documented within the first 3 cycles of the therapy. The toxicity assessment was based on the National Cancer Institute Common Toxicity Criteria Adverse Event reporting guidelines (NCI-CTC AE, version 3.0) and was done without knowledge of the genotyping results. No distinct therapy protocol appeared to be particularly linked to higher unwanted toxicity.
###end p 26
###begin title 27
PCR amplification and mutational analysis
###end title 27
###begin p 28
###xml 107 111 107 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DPYD</italic>
###xml 209 213 209 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Seck1">[28]</xref>
###xml 232 236 232 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DPYD</italic>
###xml 338 342 338 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Gross2">[29]</xref>
DNA was prepared from frozen EDTA-blood samples using standard techniques. The entire coding region of the DPYD gene was amplified with 23 primer pairs corresponding to 23 exons and the exon-intron-boundaries [28]. The detection of DPYD sequence variants was carried out by denaturing HPLC analysis and sequencing as previously described [29].
###end p 28
###begin title 29
Statistical methods
###end title 29
###begin p 30
###xml 54 55 54 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 110 114 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Barrett1">[30]</xref>
The pairwise linkage disequilibrium measures, D' and r2, were calculated using the software package Haploview [30].
###end p 30
###begin p 31
###xml 60 67 <span type="species:ncbi:9606">patient</span>
Association between affection state (5-FU tolerance) of the patient sample and genotypes was tested by logistic regression analysis including age at treatment and sex as covariates. Different single-marker association models were tested: no specific inheritance model (considers all genotypic effects), the recessive model, which contrasts one homozygote against the other pooled genotypes (both alleles as recessive alleles were tested) and a trend model which assumes an allele dose effect. Corrections for multiple comparisons within each model were considered using a global permutation test (1000 permutations). In addition, a two-marker sliding window approach was performed to narrow down the association signal.
###end p 31
###begin p 32
###xml 147 154 <span type="species:ncbi:9606">patient</span>
Fisher's exact test was applied to assess differences in the distribution of polymorphisms with respect to toxicity in tumor-type matched pairs of patient samples.
###end p 32
###begin p 33
###xml 215 216 215 216 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</sub>
###xml 218 219 218 219 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">u</sub>
###xml 224 225 224 225 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</sub>
###xml 239 240 239 240 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</sub>
###xml 359 360 359 360 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">u</sub>
The proportion of the risk of side effects in the 496A>G carriers that could be attributed to the G-allele (attributable risk in the "exposed") was calculated by the following formula: attributable risk % (AR%) = (Ie-Iu) / Iex100, where 'Ie' is the incidence of side effects in the combined group of heterozygous and homozygous carriers of the G-allele and 'Iu' is the incidence of side effects in the group with the major genotype (AA).
###end p 33
###begin title 34
Results
###end title 34
###begin title 35
###xml 31 38 <span type="species:ncbi:9606">patient</span>
Characteristics of the initial patient cohort
###end title 35
###begin p 36
###xml 215 223 215 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004003.s002">Table S2</xref>
###xml 468 476 468 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004003.s002">Table S2</xref>
###xml 105 113 <span type="species:ncbi:9606">patients</span>
###xml 413 421 <span type="species:ncbi:9606">patients</span>
###xml 459 466 <span type="species:ncbi:9606">patient</span>
###xml 478 485 <span type="species:ncbi:9606">patient</span>
###xml 660 663 <span type="species:ncbi:9606">man</span>
###xml 665 672 <span type="species:ncbi:9606">patient</span>
###xml 1130 1138 <span type="species:ncbi:9606">patients</span>
Based on common toxicity criteria guidelines (NCI-CTC AE, version 3.0), we obtained a total of 39 cancer patients presenting with grade III and IV toxicity after treatment with a 5-FU-containing (poly)chemotherapy (Table S2, supporting information). Thirty-seven of these individuals showed recovery from the encountered adverse events following complete elimination of 5-FU or corresponding dose reductions. Two patients had a fatal outcome: One 62 year-old patient (Table S2, patient #26) with rectal cancer developed severe neutropenia, mucositis and diarrhea after 5-FU administration and died to the sequela of a toxic shock syndrome. Another 76 year-old man (patient #17) with locally advanced adenocarcinoma of the esophagogastric junction died during the first 5-FU/oxaliplatin application. He had reported severe angina pectoris and suffered a cardiac arrest. Immediate resuscitation remained unsuccessful. Although autopsy did not reveal structural damages of coronary arteries or heart muscles, his death was attributed to 5-FU-induced cardiac toxicity, possibly due to coronary spasm. In the majority of our recruited patients (n = 89), however, 5-FU-based chemotherapy was well tolerated or caused only mild toxicity (NCI-CTC AE grading I-II).
###end p 36
###begin title 37
Association of distinct polymorphisms with enhanced 5-FU-induced toxicity
###end title 37
###begin p 38
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DPYD</italic>
###xml 241 245 241 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DPYD</italic>
###xml 252 259 252 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004003-t002">Table 2</xref>
###xml 352 353 352 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 412 418 412 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004003-g001">Fig. 1</xref>
###xml 434 435 434 435 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 521 525 521 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DPYD</italic>
###xml 551 555 551 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Hormozian1">[31]</xref>
###xml 557 561 557 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Maekawa1">[32]</xref>
###xml 74 81 <span type="species:ncbi:9606">patient</span>
Scanning the entire reading frame of the DPYD gene in the above described patient cohort, we identified 18 different single nucleotide exchanges and one novel frameshift mutation, c.1109delTA (p.Ile370LysfsX4), distributed across the entire DPYD gene (Table 2). The linkage disequilibrium (LD) structure based on 18 SNPs shows considerable low D' and r2 values with only two genetic regions showing moderate LD (Fig. 1). This D' and r2 pattern may indicate a large recombination-rich DNA interval comprising the complete DPYD gene as suggested before [31], [32].
###end p 38
###begin title 39
###xml 50 54 50 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DPYD</italic>
Linkage disequilibrium (LD) structure based on 18 DPYD variants.
###end title 39
###begin p 40
###xml 23 24 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 73 82 73 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Barrett1">[ref. 30]</xref>
Pairwise LD measures (r2) calculated with the software package Haploview [ref. 30] are shown. The strongest LD region is highlighted.
###end p 40
###begin title 41
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DPYD</italic>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
Allele frequencies of DPYD variants in patients with/without enhanced toxicity.
###end title 41
###begin p 42
Reference sequences are based on NCBI Accession No. NM_000110.3 (mRNA).
###end p 42
###begin p 43
Published in Seck et al, 2005 (Ref.28).
###end p 43
###begin p 44
###xml 10 18 <span type="species:ncbi:9606">patients</span>
Cohort of patients analyzed by the Zentrum fur Humangenetik und Laboratoriumsmedizin, Martinsried, Germany.
###end p 44
###begin p 45
not analyzed.
###end p 45
###begin p 46
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DPYD</italic>
###xml 194 195 194 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 204 213 204 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p (trend)</italic>
###xml 279 292 279 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p (corrected)</italic>
###xml 372 385 372 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p (corrected)</italic>
###xml 419 426 419 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004003-t002">Table 2</xref>
###xml 726 727 726 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 987 991 987 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Gross1">[25]</xref>
###xml 993 997 993 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Mattison1">[33]</xref>
###xml 673 681 <span type="species:ncbi:9606">patients</span>
Analysis of the DPYD genotypes revealed evidence of a strong allele-dose-dependent association with the appearance of toxicity for two moderately correlated variants, IVS10-15t>c and c.496A>G (r2 = 0.68; p (trend)<0.001), even after adjustment for multiple testing (IVS10-15t>c: p (corrected) = 0.009, odds ratio (OR) = 3.88 [95% confidence interval 1.71-8.78]; c.496A>G: p (corrected) = 0.002; OR = 4.58 [1.95-10.75]; Table 2). Regarding the two-marker sliding window approach the strongest association signals were observed for those haplotype combinations which included the marker c.496A>G (e.g. marker combination c.496A>G and IVS5+18 g>a: haplotype G/G; frequency in patients with and without toxicity; 0.256 vs. 0.088; p = 0.0003). This suggests that the single marker association signal is mainly due to the functional SNP c.496A>G causing a non-synonymous amino acid substitution (p.Met166Val) at a highly conserved position and within a conserved three-dimensional environment [25], [33].
###end p 46
###begin p 47
###xml 344 352 344 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004003.s002">Table S2</xref>
###xml 683 690 683 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004003-t002">Table 2</xref>
###xml 15 22 <span type="species:ncbi:9606">patient</span>
###xml 245 252 <span type="species:ncbi:9606">patient</span>
###xml 331 338 <span type="species:ncbi:9606">patient</span>
###xml 399 407 <span type="species:ncbi:9606">patients</span>
###xml 447 455 <span type="species:ncbi:9606">patients</span>
###xml 537 545 <span type="species:ncbi:9606">patients</span>
In the studied patient cohort, the attributable risk to suffer from severe drug-adverse effects due to the 496G-allele was 56.9%. Further clinical support of the relevance of this polymorphism with respect to enhanced toxicity may come from the patient samples: one case of cardiac death concerned a heterozygous G-allele carrier (patient #17, Table S2) and all homozygous carriers of the G-allele (patients #16, 23, 31) fell into the subgroup of patients with enhanced toxicity. The considerable lower frequency of the c.496G-allele in patients with good tolerance of 5-FU (0.082) was identical with the population-based control group (0.081) consisting of 607 healthy individuals (Table 2).
###end p 47
###begin title 48
###xml 56 63 <span type="species:ncbi:9606">patient</span>
Reevaluation of the association data with an additional patient cohort
###end title 48
###begin p 49
###xml 134 141 134 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004003-t002">Table 2</xref>
###xml 822 825 822 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Saif1">[9]</xref>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
To corroborate our findings we included a second cohort of 53 patients which has been collected and analyzed independently (cohort 2, Table 2). All patients had reacted with severe drug-adverse events following treatment with a 5-FU- or capecitabine-based chemotherapy regimen. The c.496A>G minor allele frequency of this second cohort (0.23) showed no relevant difference compared to the initial toxicity group (0.26). In this context it is interesting that three c.496G allele carriers encountered severe toxicity (mainly diarrhea and hand-foot-syndrome) after application of the orally available 5-FU prodrug capecitabine, which resulted in cessation of the chemotherapy in two individuals. These observations may emphasize a risk for drug intolerance due to DPD involvement in chemotherapy regimens using capecitabine [9].
###end p 49
###begin p 50
###xml 147 151 147 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DPYD</italic>
###xml 169 178 169 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p (trend)</italic>
###xml 186 199 186 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p (corrected)</italic>
###xml 342 346 342 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DPYD</italic>
###xml 25 32 <span type="species:ncbi:9606">patient</span>
Analysis of the combined patient sample with toxicity (initial and second cohort; n = 92) yielded a significant dose-dependent association for the DPYD marker c.496A>G (p (trend)<0.001; p (corrected) = 0.001; OR = 4.42 [2.12-9.23]. In addition, no significant association with fluoropyrimidine-related side effects was observed for the other DPYD polymorphisms, gender and age at treatment.
###end p 50
###begin title 51
Incidence of c.496A>G in tumor type-matched sets of samples
###end title 51
###begin p 52
###xml 177 184 177 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004003-t003">Table 3</xref>
###xml 646 647 646 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 167 175 <span type="species:ncbi:9606">patients</span>
###xml 222 230 <span type="species:ncbi:9606">patients</span>
###xml 305 312 <span type="species:ncbi:9606">patient</span>
Since distinct DPYD polymorphisms could be correlated with a particular type of tumor, we additionally re-evaluated our association data in tumor-type matched sets of patients (Table 3). Gastroesophageal and breast cancer patients reflected the results obtained in toxicity and control cases of the whole patient population. No association of c.496A>G or IVS10-15t>c with enhanced toxicity was achieved for colorectal carcinoma cases, although a trend towards higher prevalence of these variants was linked to side effects following a fluoropyrimidine/platinum therapy (e.g. c.496A>G frequency in toxicity versus control group: 0.29 versus 0.17; p = 0.378).
###end p 52
###begin title 53
###xml 63 70 <span type="species:ncbi:9606">patient</span>
Comparison of control and toxicity cases in tumor-type matched patient samples.
###end title 53
###begin p 54
Comparison of frequencies in toxicity grade 0-II versus III-IV using Fisher's exact test.
###end p 54
###begin title 55
###xml 52 59 <span type="species:ncbi:9606">patient</span>
Low frequency of clear deleterious mutations in our patient population
###end title 55
###begin p 56
###xml 386 388 386 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">st</sup>
###xml 429 437 429 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004003.s002">Table S2</xref>
###xml 738 742 738 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-vanKuilenburg3">[21]</xref>
###xml 830 838 830 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004003.s002">Table S2</xref>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
###xml 338 345 <span type="species:ncbi:9606">patient</span>
###xml 416 423 <span type="species:ncbi:9606">patient</span>
###xml 817 824 <span type="species:ncbi:9606">patient</span>
The well-described exon-14-skipping mutation IVS14+1g>a which is related to DPD deficiency occurred in only five of all 92 cases with toxic side effects. This splice-site mutation was not observed in patients with good tolerance of a fluoropyrimidine therapy. Another yet undescribed truncating mutation (c.1109delTA) was discovered in a patient who suffered fatal toxicity during the 1st cycle of 5-FU monotherapy (patient #26, Table S2). The previously unknown frameshift mutation in exon 10 leads to a stop codon at position 374. Finally, the missense mutation 2846 A>T (p.Asp949Val), which is assumed to interfere with iron-sulfur-cluster formation and thus, with the electron transfer during the catalytic reaction of the enzyme DPD [21], was only found in one individual with severe enterotoxicity of grade IV (patient #29, Table S2).
###end p 56
###begin title 57
Discussion
###end title 57
###begin p 58
###xml 27 31 27 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DPYD</italic>
###xml 419 422 419 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Saif1">[9]</xref>
###xml 424 428 424 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Ciccolini1">[34]</xref>
###xml 430 434 430 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Largillier1">[35]</xref>
###xml 614 618 614 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DYPD</italic>
###xml 714 718 714 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DPYD</italic>
###xml 823 827 823 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-CollieDuguid1">[18]</xref>
###xml 829 833 829 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Magne1">[19]</xref>
###xml 957 959 957 959 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sup>
###xml 980 984 980 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Mattison2">[36]</xref>
###xml 1047 1051 1047 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Ciccolini1">[34]</xref>
###xml 1053 1057 1053 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Zhou1">[37]</xref>
###xml 1059 1063 1059 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-BenFredj1">[38]</xref>
###xml 1317 1321 1317 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Mercier1">[39]</xref>
###xml 1411 1415 1411 1415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Lazar1">[40]</xref>
###xml 1586 1590 1586 1590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-DiPaolo1">[41]</xref>
###xml 201 209 <span type="species:ncbi:9606">patients</span>
###xml 507 515 <span type="species:ncbi:9606">patients</span>
###xml 1710 1718 <span type="species:ncbi:9606">patients</span>
Sequence variations in the DPYD gene have been shown to influence the breakdown of the common anticancer drug 5-FU and to provoke severe drug-adverse effects during systemic 5-FU-application in cancer patients. Moreover, the integrity of the 5-FU degradation pathway appears to be of similar importance concerning the application of newly introduced fluoropyrimidine drugs which are intracellularly converted into 5-FU [9], [34], [35]. Thus, these observations warrant systematic detection of DPD-deficient patients prior to fluoropyrimidine administration. However, a practical and reliable pretreatment test for DYPD variants or mutations has not been available so far due to the high genetic variability of the DPYD coding region and the rare occurrence of clear deleterious mutations, at least in Caucasian populations [18], [19]. For this reason, several functional methods designed for the rapid prediction of a (partial) DPD deficiency such as the 2-13C-uracil breath test [36] or the determination of plasmatic uracil/dihydrouracil ratios [34], [37], [38] have been introduced in the meantime. Mercier and colleagues reported very recently, that prospective evaluation of the functional DPD status followed by corresponding 5-FU dose tailoring led to a 2- fold decrease in the occurrence of severe toxicities [39]. Nevertheless, these methods have not found broad application in clinical routine so far [40], not least because these kind of analyses require a special equipment. In addition, a lack of correlation between DPD activity measurements and 5-FU toxicity was assumed [41]. Clearly, methodologies based on genetic testing for clinically relevant SNPs would offer the simplest way to identify patients at the highest risk of potentially life-threatening drug-adverse events.
###end p 58
###begin p 59
###xml 119 123 119 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DPYD</italic>
###xml 604 608 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-vanKuilenburg4">[24]</xref>
###xml 610 614 610 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Gross1">[25]</xref>
###xml 696 700 696 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Johnson1">[26]</xref>
###xml 844 848 844 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-DiPaolo1">[41]</xref>
###xml 988 992 988 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Mattison1">[33]</xref>
###xml 1226 1233 1226 1233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DPYD*2A</italic>
###xml 1601 1605 1601 1605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Magne1">[19]</xref>
###xml 1607 1611 1607 1611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Schwab1">[20]</xref>
###xml 1738 1742 1738 1742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Lazar1">[40]</xref>
###xml 1744 1748 1744 1748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Morel1">[15]</xref>
###xml 189 197 <span type="species:ncbi:9606">patients</span>
###xml 595 603 <span type="species:ncbi:9606">patients</span>
###xml 1257 1265 <span type="species:ncbi:9606">patients</span>
###xml 1485 1492 <span type="species:ncbi:9606">patient</span>
###xml 1900 1908 <span type="species:ncbi:9606">patients</span>
With respect to the development of a genetic test, we conducted a systematic analysis of the coding region of the gene DPYD and compared the incidence of commonly found SNPs between cancer patients with good and with poor tolerance of a fluoropyrimidine-based chemotherapy. We observed a significant allele-dose-dependent association of the non-synonymous sequence aberration c.496A>G (p.Met166Val) with the phenotype of enhanced toxicity of grade III/IV. The methionine-valine exchange resulting from the c.496A>G transition has been already implicated in a deleterious effect in DPD deficient patients [24], [25], but conflicting results have been reported for its influence on enzyme activity [26]. While DPD activity measured in peripheral blood mononuclear cells might be unrelated to 5-FU toxicity according to a study by Di Paolo et al. [41], the high conservation of the mutation site during evolution strongly speaks in favour of a biological relevance of this amino acid change [33]. Most strikingly, carriers of the c.496A>G genotype constituted more than 43% of the individuals with severe drug-adverse effects in our study. In contrast to this high prevalence, the classical exon-14-skipping mutation IVS14+1g>a (DPYD*2A) occurred in only five patients (5.4%) of overall 92 toxicity cases. Moreover, another yet undescribed truncating mutation, c.1109delTA (p.Ile370LysfsX4), and a putative deleterious missense mutation (c.2846A>T) were detected each once in the studied patient population. Thus, compared to other recent publications which reported either marginal predictive potential [19], [20] or a reduction of severe adverse effects of up to 27% by prospective genotyping for the mutations IVS14+1g>a and/or c.2846A>T [40], [15], the detection of a more frequent polymorphism associated with an elevated risk for fluoropyrimidine intolerance would help to identify much more risk patients. These individuals could benefit from careful individual dose adaptation of 5-FU or 5-FU prodrugs.
###end p 59
###begin p 60
###xml 178 185 <span type="species:ncbi:9606">patient</span>
###xml 621 629 <span type="species:ncbi:9606">patients</span>
A potential bias of our study could have been introduced by association of c.496A>G with a certain tumor type. In this context, no discrepancy with results obtained in the whole patient population was obvious regarding breast or gastroesophageal cancers. In addition, the incidence of c.496A>G in the respective control cases without enhanced toxicity did not exceed the frequency measured in 607 healthy individuals speaking against a relation of c.496A>G with the development of these cancers. In contrast to these results, no significant correlation of c.496A>G with toxicity could be determined for colorectal cancer patients yet because the sequence aberration displayed increased incidence (compared to healthy volunteers) in toxicity as well as in control cases. However, due to the rather small number of control cases (n = 15) which were available for this type of cancer, the amount of 496G-allele carriers in the control group might have been overestimated and needs further evaluation with higher case numbers.
###end p 60
###begin p 61
###xml 160 164 160 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Schwab1">[20]</xref>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
###xml 359 367 <span type="species:ncbi:9606">patients</span>
###xml 487 495 <span type="species:ncbi:9606">patients</span>
###xml 694 702 <span type="species:ncbi:9606">patients</span>
###xml 956 964 <span type="species:ncbi:9606">patients</span>
###xml 1083 1091 <span type="species:ncbi:9606">patients</span>
###xml 1205 1213 <span type="species:ncbi:9606">patients</span>
On the other side, the different results obtained with colorectal cancer patients could explain the discrepancy between our findings and those of Schwab et al. [20] concerning a major role of c.496A>G in severe drug-adverse effects. The recent study by Schwab et al. which suggested a limited role of genetic factors for severe 5-FU toxicity relies mainly on patients with colorectal carcinoma. Another reason for the different observations may be linked to the type of treatment of the patients, as Schwab et al. have restricted their clinical trial to 5-FU monotherapy. Whereas only 19% of gastroesophageal cancers were treated with 5-FU+/-folinic acid in our study, 45% of colorectal cancer patients received such treatment. Accordingly, less pronounced association with the variant 496A>G was found - although at low case numbers - for 5-FU alone or with chemoradiation yielding 496G-allele frequencies of 0.14 (n = 11) versus 0.105 (n = 19) in cancer patients with and without severe drug-adverse events. However, a high prevalence of the c.496A>G genotype was confirmed in our patients with severe toxicity regarding 5-FU/ platinum or anthracycline-containing regimens (frequency of 496G-alleles in patients with and without severe toxicity: 0.25 (n = 30) versus 0.08 (n = 51) for 5-FU/folinic acid/platinum drug therapies; 0.43 (n = 7) versus 0.05 (n = 10) for FEC treatment). These data may suggest that the influence of c.496A>G is more obvious in the presence of additional, drugs.
###end p 61
###begin p 62
###xml 93 97 93 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Johnson1">[26]</xref>
###xml 238 242 238 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-VanKuilenburg2">[42]</xref>
###xml 304 308 304 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Reerink1">[43]</xref>
Since relatively high DPD activity has been reported for c.496A>G carriers by Johnson et al. [26] we cannot rule out that the severe c.496A>G-associated phenotype is due to a cumulative effect caused by toxic fluoropyrimidine catabolites [42] and cytotoxicity of other components of the polychemotherapy [43]. Nevertheless, our data obtained on a high number of toxicity cases (n = 92), comparable to the study by Schwab et al., show a clear, clinically important association which reached high significance in gastroesophageal and breast cancers.
###end p 62
###begin p 63
###xml 53 57 53 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Bosch1">[44]</xref>
###xml 280 284 280 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DPYD</italic>
###xml 335 339 335 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004003-Zhang1">[45]</xref>
With respect to the complexities in pharmacogenomics [44], evaluation of different therapy regimens and tumor types may lead to a better understanding of the role of genetic factors in fluoropyrimidine-related drug-adverse-events. Gene chip analyses for the detection of relevant DPYD variants as previously introduced by Zhang et al. [45] might then be the best choice in a future clinical setting.
###end p 63
###begin title 64
Limitations
###end title 64
###begin p 65
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Although this initial study relies on a relatively high number of patients with severe toxicity, case numbers are still limited. Analysis of further cases with toxic side effects is now utterly required taking also into account the specific type of tumor and treatment protocol.
###end p 65
###begin title 66
Supporting Information
###end title 66
###begin p 67
Treatment protocols with respect to the type of cancer
###end p 67
###begin p 68
(0.04 MB DOC)
###end p 68
###begin p 69
Click here for additional data file.
###end p 69
###begin p 70
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients with grade III-IV toxicity, completely analyzed in the DPYD gene
###end p 70
###begin p 71
(0.10 MB DOC)
###end p 71
###begin p 72
Click here for additional data file.
###end p 72
###begin p 73
###xml 273 281 <span type="species:ncbi:9606">patients</span>
###xml 330 338 <span type="species:ncbi:9606">patients</span>
We are grateful to Dr. M. Stauch (Praxis fur Hamatologie und Onkologie, Kronach), Dr. M. deWit (Universitatsklinikum Hamburg-Eppendorf, Hamburg), Dr. Schafer (Klinikum Neuperlach, Munich) and Dr. Montemurro (Universitatsklinik Greifswald) for providing us blood samples of patients with drug-adverse effects. We wish to thank all patients participating in this study. We greatly appreciate the technical assistance of V. Kellnberger, M. Voggenreiter and K. Papsdorf.
###end p 73
###begin title 74
References
###end title 74
###begin article-title 75
Chemotherapy of advanced gastric cancer.
###end article-title 75
###begin article-title 76
Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers.
###end article-title 76
###begin article-title 77
Therapy for metastatic colorectal cancer.
###end article-title 77
###begin article-title 78
Adjuvant strategies in breast cancer: new prospectives, questions and reflections at the end of 2007 St Gallen International Expert Consensus Conference.
###end article-title 78
###begin article-title 79
Adjuvant therapy for colon cancer.
###end article-title 79
###begin article-title 80
Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile.
###end article-title 80
###begin article-title 81
Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology.
###end article-title 81
###begin article-title 82
Dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil associated toxicity.
###end article-title 82
###begin article-title 83
###xml 24 32 <span type="species:ncbi:9606">patients</span>
Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
###end article-title 83
###begin article-title 84
###xml 39 44 <span type="species:ncbi:9606">human</span>
cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria.
###end article-title 84
###begin article-title 85
The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil.
###end article-title 85
###begin article-title 86
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
###end article-title 86
###begin article-title 87
###xml 116 124 <span type="species:ncbi:9606">patients</span>
Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients.
###end article-title 87
###begin article-title 88
Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations.
###end article-title 88
###begin article-title 89
Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance.
###end article-title 89
###begin article-title 90
Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects.
###end article-title 90
###begin article-title 91
###xml 91 99 <span type="species:ncbi:9606">patients</span>
High prevalence of the IVS14+1G> A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.
###end article-title 91
###begin article-title 92
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Known variant DPYD alleles do not explain DPD deficiency in cancer patients.
###end article-title 92
###begin article-title 93
###xml 72 80 <span type="species:ncbi:9606">patients</span>
Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity.
###end article-title 93
###begin article-title 94
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
###end article-title 94
###begin article-title 95
Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure.
###end article-title 95
###begin article-title 96
Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W.
###end article-title 96
###begin article-title 97
Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil.
###end article-title 97
###begin article-title 98
###xml 77 85 <span type="species:ncbi:9606">patients</span>
Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene.
###end article-title 98
###begin article-title 99
###xml 90 98 <span type="species:ncbi:9606">patients</span>
Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects.
###end article-title 99
###begin article-title 100
Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype.
###end article-title 100
###begin article-title 101
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
###end article-title 101
###begin article-title 102
Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals.
###end article-title 102
###begin article-title 103
High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism.
###end article-title 103
###begin article-title 104
Haploview: analysis and visualization of LD and haplotype maps.
###end article-title 104
###begin article-title 105
FRA1E common fragile site breaks map within a 370kilobase pair region and disrupt the dihydropyrimidine dehydrogenase gene (DPYD).
###end article-title 105
###begin article-title 106
Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences.
###end article-title 106
###begin article-title 107
A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms.
###end article-title 107
###begin article-title 108
A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.
###end article-title 108
###begin article-title 109
###xml 59 67 <span type="species:ncbi:9606">patients</span>
Pharmacogenetics of capecitabine in advanced breast cancer patients.
###end article-title 109
###begin article-title 110
Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test.
###end article-title 110
###begin article-title 111
###xml 124 132 <span type="species:ncbi:9606">patients</span>
The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
###end article-title 111
###begin article-title 112
###xml 153 161 <span type="species:ncbi:9606">patients</span>
The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.
###end article-title 112
###begin article-title 113
Prospective phenotypic screening for DPD deficiency prior to 5-FU administration: Decrease in toxicity, not in efficacy.
###end article-title 113
###begin article-title 114
Pharmacogenetics in oncology: 5-fluorouracil and the dihydropyrimidine dehydrogenase.
###end article-title 114
###begin article-title 115
###xml 113 121 <span type="species:ncbi:9606">patients</span>
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.
###end article-title 115
###begin article-title 116
###xml 84 92 <span type="species:ncbi:9606">patients</span>
Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin.
###end article-title 116
###begin article-title 117
###xml 93 101 <span type="species:ncbi:9606">patients</span>
5FU and oxaliplatin-containing chemotherapy in two dihydropyrimidine dehydrogenase-deficient patients.
###end article-title 117
###begin article-title 118
Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
###end article-title 118
###begin article-title 119
###xml 182 190 <span type="species:ncbi:9606">patients</span>
DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients.
###end article-title 119
###begin p 120
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 120
###begin p 121
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by the Kommission fur klinische Forschung (KKF) der Technischen Universitat Munchen (No. 18-02), by the Deutsche Krebshilfe e.V. (DKH No. 107352) and by the German National Genome Research Network (NGFN) (No. 01GS0465). The funding organizations had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 121

